User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
A 25 year-old male who has been taking finasteride (1mg/day) for 4 months and then switching to dutasteride (0.5mg twice per week) for 20 months, with positive results; the difference between finasteride and dutasteride is discussed.
The user is 4 months into using a treatment with 5mg Dutasteride and 1.25mg Minoxidil daily, along with vitamin K2 and weekly dermastamping. They report some hairline improvement but no noticeable change in the crown area yet.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
The user reported positive results with thicker and denser hair after four months of taking 1mg oral finasteride daily, without using minoxidil. Some users discussed potential side effects like mild testicular ache and debated the timing and benefits of adding minoxidil to the regimen.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
A 24-year-old male experienced significant hair regrowth after 14 months of treatment with 0.5mg dutasteride and 5mg minoxidil, with no side effects reported. He plans to consider a hair transplant for his hairline, as the treatment did not improve that area.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.